Dr. Michael Joseph Leukam, MD

Dr. Leukam practices at Beth Israel Deaconess Medical Center in Boston, Massachusetts, part of Beth Israel Lahey Health.

Dr. Leukam's NPI, 1801209853, was assigned on June 7, 2014. Dr. Leukam graduated from Loyola University of Chicago, Stritch School of Medicine in 2014. Dr. Leukam holds Massachusetts license ETL5016.

Dr. Leukam's primary practice is Beth Israel Deaconess Medical Center, at 330 Brookline Avenue, Boston, MA 02215 in Suffolk County. The practice phone is (617) 667-7000.

Dr. Leukam's primary practice is Beth Israel Deaconess Medical Center in Boston, Massachusetts, part of Beth Israel Lahey Health. Dr. Leukam is also affiliated with Beth Israel Deaconess Hospital-Plymouth. The medical group on file is Beth Israel Deaconess Medical Center. Dmand AI also links Dr. Leukam to 2 more medical groups, each named with a free account. Dr. Leukam's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Leukam practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Leukam's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Leukam's licenses on file in 2 states: Massachusetts and Illinois.

CMS data shows 831 Medicare services from Dr. Leukam across 8 procedure codes in 2024, for 193 Medicare patients. Medicare paid $71,671 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 193 Medicare patients who saw Dr. Leukam in 2024. The largest group is 75 to 84, with 82 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 22% are also on Medicaid. Their average risk score is 2.59, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Leukam's median patient age at 72, with 46% women.

In 2024, Dr. Leukam wrote 137 Medicare Part D claims for 34 patients. 82% of them were for generic drugs. CMS names the drug for 34 of them, across 2 drugs with 11 or more claims each, at $7,464 in total drug cost. In 2023, CMS named 45 claims across 3 drugs.

Dr. Leukam accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Leukam as offering telehealth.

Dmand AI links 4 papers to Dr. Leukam, published from 2018 to 2024. 2019 was the busiest year, with 2. The most frequent topics are T-Lymphocytes. Dr. Leukam's most frequent co-authors are James Godfrey, MD, Stephen M. Ansell, MD and Kirk Edward Cahill, MD.

Dmand AI links Dr. Leukam to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Disease Attributes and Pathological Conditions, Signs and Symptoms. Open Payments lists research payments to Dr. Leukam that name 1 trial.

CMS Open Payments shows 16 general payments to Dr. Leukam from 6 drug and device companies from 2019 to 2025. Honoraria make up the largest share, 62% of the total. ADC Therapeutics America, Inc. paid the most, $16,586. It also lists 6 research payments totaling $878 in 2023, naming 1 clinical trial.

Dr. Leukam graduated from Loyola University of Chicago, Stritch School of Medicine in 2014.